

*** 부록 1. - 문헌의 배제사유**

1. 국외문헌

번호	문헌	배제사유
1	Berry, W., M. Elkordy, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?	진단기준위배
2	Jeremic, B., D. J. Zivic, et al. Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.	두경부전이암
3	Jeremic, B., L. Zivic, et al. Radiotherapy and cisplatin in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.	두경부전이암
4	Pouessel, D., S. Culine, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.	진단기준위배
5	Zouhair, A., P. A. Coucke, et al. Prospective study of accelerated postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck	두경부전이암
6	Argiris, A., S. M. Smith, et al. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.	두경부전이암
7	Culine, S., M. Fabbro, et al. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.	치료법부적합
8	Karapetis, C. S., D. Yip, et al. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.	진단기준위배
9	Sumi, H., K. Itoh, et al. Treatable subsets in cancer of unknown primary origin.	후향적차트리뷰
10	Voog, E., Y. Merrouche, et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.	진단기준위배
11	Lofts, F. J., H. Gogas, et al. Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy	진단기준위배

	regimen (CFTam).	
12	Hess, K. R., M. C. Abbruzzese, et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.	진단기준위배
13	Warner, E., R. Goel, et al. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).	진단기준위배
14	van der Gaast, A., J. Verweij, et al. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.	진단기준위배
15	Khansur, T., C. Allred, et al. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.	진단기준위배
16	de Campos, E. S., L. P. Menasce, et al. Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).	진단기준위배
17	Nole, F., M. Colleoni, et al. Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.	진단기준위배
18	Pavlidis, N., P. Kosmidis, et al. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.	진단기준위배
19	al-Idrissi, H. Y. Combined 5-fluorouracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site.	진단기준위배
20	Sulkes, A., B. Uziely, et al. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.	진단기준위배
21	Spigel, D. R., J. D. Hainsworth, et al. Neuroendocrine Carcinoma of Unknown Primary Site.	진단기준위배
22	Lazaridis, G., G. Pentheroudakis, et al. Liver metastases from cancer of unknown primary(CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.	진단기준위배
23	Greco, F. A., G. I. Rodriguez, et al. Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: A	치료법부적합

	Minnie Pearl Cancer Research Network phase II trial.	
24	Culine, S., M. Ycho, et al. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.	진단기준위배
25	Maartense, E., H. C. Kluin-Nelemans, et al. Carcinoma of unknown primary site: Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide.	중복출판
26	Giralt, J. L., J. Gonzalez, et al. Brain metastases in patients with no known primary tumor: The role of stereotactic radiosurgery.	두경부전이암
27	Grau, C., L. V. Johansen, et al. Cervical lymph node metastases from unknown primary tumours: Results from a national survey by the Danish Society for Head and Neck Oncology.	두경부전이암
28	Greco, F. A., J. B. Erland, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin.	중복출판
29	Amichetti, M., M. Romano, et al. Hyperthermia and radiotherapy for inoperable squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site.	두경부전이암
30	Culine, S., M. Fabbro, et al. Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy.	치료법 부적합
31	Greco, F. A. and J. D. Hainsworth The evolving role of paclitaxel for patients with carcinoma of unknown primary site.	중복출판
32	Colletier, P. J., A. S. Garden, et al. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: Outcomes and patterns of failure.	두경부전이암
33	Medini, E., A. M. Medini, et al. The management of metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary.	두경부전이암
34	Hainsworth, J. D., J. B. Erland, et al. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.	중복출판
35	Galan, M. C., J. J. Grau, et al. Treatment with adriamycin and ftorafuracil in carcinoma of unknown origin.	원저가 아님
36	Lenzi, R., M. N. Raber, et al. Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine.	진단기준위배
37	Van der Gaast, A., S. C. Henzen-Logmans, et al. Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.	진단기준위배
38	Hainsworth, J. D., D. H. Johnson, et al. The role of	진단기준위배

	cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.	
39	Wagener, D. J. T., P. H. M. De Mulder, et al. Phase II trial of cisplatin for adenocarcinoma of unknown primary site.	진단기준위배
40	Van der Gaast, A., J. Verweij, et al. Carcinoma of unknown primary: Identification of a treatable subset?	진단기준위배
41	Kambhu, S. A., D. P. Kelsen, et al. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results.	진단기준위배
42	Jacobs, M. C., M. Eisenberger, et al. Carboplatin (CBDCA) and radiotherapy for stage Ivcarcinoma of the head and neck: A phase I-II study.	두경부전이암
43	Treat, J., S. C. Falchuk, et al. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.	진단기준위배
44	Hainsworth, J. D., E. P. Wright, et al. Poorly differentiated carcinoma of unknown primary site: Correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.	진단기준위배
45	Milliken, S. T., M. H. N. Tattersall, et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.	진단기준위배
46	Goldberg, R. M., F. P. Smith, et al. 5-Fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.	진단기준위배
47	Madani, I., L. Vakaet, et al. Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer.	두경부전이암
48	Palmeri, S., A. Misino, et al. Cisplatin (CDDP), gemcitabine (Gem), and paclitaxel (Tax) or vinorelbine (VNR) in metastatic carcinoma of unknown primary (CUP).	중복출판
49	Lortholary, A., S. Culine, et al. Cisplatin in combination with either gemcitabine (GC) or irinotecan (IC) in carcinomas of unknown primary (CUP): results of a randomized phase II study.	중복출판
50	Dowell, J. E., A. M. Garrett, et al. A randomized phase II comparison of carboplatin (C) and etoposide (E) with paclitaxel (T), 5-fluorouracil (F), and leucovorin (L) in patients (PTS) with carcinoma from an unknown primary site (CUP).	원저가 아님
51	Falkson, C. I. and G. L. Cohen Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin.	진단기준위배
52	Jeremic, B. Metastatic squamous-cell carcinoma (SCC) of an	원저가 아님

	unknown origin primary localised to the neck. Benefit from an aggressive treatment.	
53	Eagan, R. T., T. M. Therneau, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.	진단기준위배
54	Woods, R. L., R. M. Fox, et al. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.	진단기준위배

2. 국내문헌

번호	문헌	배제사유
1	조은경, 이근석, 정철원 등 원발 부위 불명의 전이암의 예후인자	진단기준위배
2	김태용, 조용한 등 경부 림프절 종대로 발현한 원발 부위 불명의 전이암	두경부전이암
3	김규보 등 Treatment outcome of metastatic carcinoma if cervicak lymph node from ab unknown primary	두경부전이암
4	김귀언, 서창욱 등 Treatment of metastatic cervical cancerous nodes from an unknown primary site	진단기준위배
5	박인규, 윤상모 등 근원 불명 전이성 경부암의 방사선치료	두경부전이암
6	이정은 원발병소 불명암의 경부림프절 전이에서 방사선치료의 역할	두경부전이암
7	이재진, 김시영, 조경삼 등 원발부위 불명 전이암 103례의 후향적 임상분석	진단기준위배
8	최병국, 유영진 등 원발부위 불명암에 대한 PE리 복합화학요법의 효과 및 치료반응군과 생존양호군의 선별	진단기준위배

* 부록 2. - 선정된 참고문헌

1. Palmeri, S., V. Lorusso, et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study.
2. Culine, S., A. Lortholary, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
3. Assersohn, L., A. R. Norman, et al. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.[see comment].
4. Schildt, R. A., P. S. Kennedy, et al. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
5. Huebner, G., H. Link, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
6. Dowell, J. E., A. M. Garrett, et al. A randomized Phase II trial in patients with carcinoma of an unknown primary site.
7. Schuette, K., G. Folprecht, et al. Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
8. Yonemori, K., M. Ando, et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
9. Pentheroudakis, G., E. Briasoulis, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
10. Briasoulis, E., G. Fountzilas, et al. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
11. Schneider, B. J., B. El-Rayes, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
12. Hainsworth, J. D., D. R. Spigel, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
13. Pittman, K. B., I. N. Olver, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.

14. El-Rayes, B. F., A. F. Shields, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
15. Piga, A., R. Nortilli, et al. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.
16. Pouessel, D., S. Culine, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
17. Balana, C., J. L. Manzano, et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
18. Macdonald, A. G., M. C. Nicolson, et al. A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
19. Guardiola, E., X. Pivot, et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial.
20. Parnis, F. X., I. N. Olver, et al. Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
21. Briasoulis, E., H. Kalofonos, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
22. Briasoulis, E., N. Tsavaris, et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
23. Greco, F. A. and J. D. Hainsworth One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
24. Raber, M. N., J. Faintuch, et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
25. Hainsworth, J. D., D. R. Spigel, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network phase II trial.
26. Park, Y. H., B. Y. Ryoo, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
27. Mukai, H., T. Watanabe, et al. Unknown primary carcinoma: A feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
28. Greco, F. A., H. A. Burris III, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study.
29. Hainsworth, J. D., H. A. Burris III, et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: Results of a Phase II trial.

30. Hainsworth, J. D., H. A. Burris III, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A Phase II trial of the Minnie Pearl Cancer Research Network.
31. Lenzi, R., M. N. Raber, et al. A pilot study of paclitaxel in previously treated patients with metastatic unknown primary carcinomas.
32. Greco, F. A., J. Gray, et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
33. Saghatelyan, M., K. Fizazi, et al. Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - Results of a prospective study.
34. Gill, I., P. Guaglianone, et al. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.

*** 부록 3. - 질평가 양식**

RCT용 질평가 양식

문헌ID		평가자		평가일	
년도			저자		
제목					

Domain	확인할 내용들	Judgment (Yes, No, Unclear)	Description
Sequence of generation	무작위 배정과정을 설명하는가? 두 군이 비교성이 있는가?		
Allocation concealment	배정 순서를 설명하는가? 대상이 어느 군에 속하는지 미리 알 수 있지 않은가?		
Blinding	눈가림을 환자와 평가자 모두에서 시행하였는가? 눈가림이 효과적으로 유지되었는가?		
	Response Survival		
Incomplete outcome	주결과변수 측정에 있어서 빠진 사람이 있는지 설명하는가?		
	있다면 왜 빠졌는지 설명하는가? (무작위된 수와 분석된 수가 같은가?)		
Selective reporting	Method 부분에서 보고한다는 것들에 대해서 결과를 모두 보고하고 있는가?		
Other source of bias	기타 비뚤림의 가능성이 있는가?		

Non-RCT 질평가 양식

문헌ID		평가자		평가일	
년도			저자		
제목					

Methodological items for non-randomized studies (MINORS)	Score*
1. 분명한 목적이 있는지.	
2. 환자가 연속적으로 포함되었는지.	
3. 사전에 마련된 프로토콜에 의해서 자료가 수집되었는가. (전향적인가를 확인)	
4. 주결과변수가 연구 목적에 부합하며 명확히 정의 되어있고, 결과는 Intention-to-treat 에 의한 결과인가.	
5. 객관적 결과변수들은 평가능가림이 이루어진채 평가되었고 주관적 결과변수들의 평가에는 이중능가림이 수행되었는가. 그렇지 않은 경우에는 능가림이 이루어질 수 없었던 이유를 기술하고 있는가.	
6. 추적기간은 적절 했는가.	
7. 탈락이 5%미만인지.	
8. 연구크기가 전향적으로 계산되었는지.	
총 점	

* 부록 4. - 자료추출 양식

CUP SR DATA EXTRACTION FORM				
문헌ID	<input style="width: 85%;" type="text"/>			
년도	<input style="width: 85%;" type="text"/>			
저자	<input style="width: 85%;" type="text"/>			
제목	<input style="width: 85%; height: 100px;" type="text"/>			
연구설계				
<input style="width: 80%;" type="text"/>	RCT			
<input style="width: 80%;" type="text"/>	SINGLE ARM TRIAL			
<input style="width: 80%;" type="text"/>	CASE SERIES			
연구 수행지	<input style="width: 85%; height: 30px;" type="text"/>			
선정기준 검사	<input style="width: 85%; height: 150px;" type="text"/>			
<input style="width: 80%;" type="text"/>	복부CT		2nd line	<input style="width: 80%;" type="text"/>
<input style="width: 80%;" type="text"/>	흉부CT			
<input style="width: 80%;" type="text"/>	흉부X-ray			
피험자	N	<input style="width: 80%;" type="text"/>	탈락	<input style="width: 80%;" type="text"/>

예후인자

연령	MEDIAN	<input type="text"/>	RANGE	<input type="text"/>
	MEAN	<input type="text"/>	SD	<input type="text"/>
성별	남	<input type="text"/>		
	여	<input type="text"/>		
전이	간전이	<input type="text"/>	뇌전이	<input type="text"/>
	뼈전이	<input type="text"/>	폐전이	<input type="text"/>
	전이부위>2	<input type="text"/>		
조직형	1. Moderate+ well diff Adeno	<input type="text"/>		
	2. PD adeno+Undiff	<input type="text"/>		
	3. NECa	<input type="text"/>		
	4. Others	<input type="text"/>		

ECOG	0	<input type="text"/>	3	<input type="text"/>
	1	<input type="text"/>	4	<input type="text"/>
	2	<input type="text"/>		<input type="text"/>

중재내용

<input type="text"/>	PLATINUM	<input type="text"/>
<input type="text"/>	Taxane	<input type="text"/>
<input type="text"/>	Antimetabolite	<input type="text"/>
<input type="text"/>	Alkylating agents	<input type="text"/>
<input type="text"/>	Vinca alkaloids	<input type="text"/>
<input type="text"/>	Etoposide	<input type="text"/>
<input type="text"/>	Anthracyclines	<input type="text"/>
<input type="text"/>	Mitomycin	<input type="text"/>
<input type="text"/>	Irinotecan	<input type="text"/>
<input type="text"/>	Cytotoxic agent	<input type="text"/>

치료결과

RESPONSE 분석

CR	
PR	
RR	

SURVIVAL	분석	
	Follow-up period	
	Median Survival	
	Confidence Interval	
	1-year Survival	
	Confidence Interval	
	2-year Survival	
	Confidence Interval	